3篇
您的检索式：作者名="Tang Mingxiang"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 3-year Treatment of Tenofovir Alafenamide vs.Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China显示文摘Background and Aims:Tenofovir alafenamide(TAF)has similar efficacy to tenofovir disoproxil fumarate(TDF)but with improved renal and bone safety in chronic hepatitis B patients studied outside of China.We report 3-year results from two phase 3 studies with TAF in China(Clinicaltrials.gov:NCT02836249 and NCT02836236).Methods:Chinese hepatitis B e antigen(HBeAg)-positive and-negative chronic hepatitis B patients with viremia and elevated alanine aminotransferase were randomized 2:1 to TAF or TDF treatment groups and treated in a double-blind fashion for 144 weeks(3 years).Efficacy responses were assessed by individual study while safety was assessed by a pooled analysis.Results:Of the 334 patients(180 HBeAg-positive and 154 HBeAg-negative)randomized and treated,baseline characteristics were similar between groups.The overall mean age was 38 years and 73%were male.The mean HBV DNA was 6.4 log10 IU/mL.The median alanine aminotransferase was 88 U/L,and 37%had a history of antiviral use.At week 144,the proportion with HBV DNA<29 IU/mL was similar among the two groups,with TAF at 83%vs.TDF at 79%,and TAF at 93%vs.TDF at 92%for the HBeAg-positive and-negative patients,respectively.In each study,higher proportions of TAF than TDF patients showed normalized alanine aminotransferase(via the American Association for the Study of Liver Diseases and the China criteria)and showed loss of HBsAg;meanwhile,the HBeAg seroconversion rates were similar.Treatment was well-tolerated among the TAF patients,who showed a smaller median decline in creatinine clearance(−0.4 vs.−3.2 mL/min;p=0.014)and less percentage change in bone mineral density vs.TDF at hip(−0.95%vs.−1.93%)and spine(+0.35%vs.−1.40%).Conclusions:In chronic hepatitis B patients from China,TAF treatment provided efficacy similar to TDF but with better renal and bone safety at 3 years. | Jinlin Hou Qin Ning Zhongping Duan You Chen Qing Xie Fu-Sheng Wang Lunli Zhang Shanming Wu Hong Tang Jun Li Feng Lin Yongfeng Yang Guozhong Gong John FFlaherty Anuj Gaggar Shuyuan Mo Cong Cheng Gregory Camus Chengwei Chen Yan Huang Jidong Jia Mingxiang Zhang GS-US-320-0110 and GS-US-320-0108 China Investigators | 2021 | Journal of Clinical and Translational Hepatology2021，9，3： | 7 |
| 2 | esveratrol inhibits necroptosis by mediating the TNF-α/RIP1/RIP3/MLKL pathway in myocardial hypoxia/reoxygenation injury显示文摘Resveratrol(RES)protects myocardial cells from hypoxia/reoxygenation(H/R)-caused injury.However,the mechanism of this effect has not been clarified.Thus,in this study,we aimed to determine whether RES attenuates H/R-induced cell necroptosis by inhibiting the tumor necrosis factor-alpha(TNF-α)/receptor-interacting protein kinase 1(RIP1)/RIP3/mixed-lineage kinase domain-like(MLKL)signaling pathway.Rat myocardial ischemia/reperfusion(I/R)models and H/R-injured cell models were constructed.Our study showed that myocardial H/R injury significantly increased the levels of TNF-α,RIP1,RIP3,and p-MLKL/MLKL by western blot analysis.Cell viability assay and 4,6-dianmidino-2-phenylindole(DAPI)-propidium iodide staining showed that the cell viability was decreased,and necroptosis was increased after myocardial H/R injury.The expressions of TNF-α,RIP1,RIP3,and p-MLKL/MLKL in H/R myocardial cells treated with different concentrations of RES were significantly downregulated.In addition,we also found that the cell viability was increased and necroptosis was decreased in dose-dependent manners when H/R-injured cells were treated with RES.In addition,the enhanced effect of TNF-αon necroptosis in myocardial H/R-injured cells was improved by RES,and the effect of RES was confirmed in vivo in I/R rats.This study also showed that RES suppresses necroptosis in H9c2 cells,which may occur through the inhibition of the TNF-α/RIP1/RIP3/MLKL signaling pathway.Our data suggest that necroptosis is a promising therapeutic target and may be a promising therapeutic target for the treatment of myocardial I/R injury. | Yongjun Hu Hongwei Pan Jianqiang Peng Jin He Mingxiang Tang Sulan Yan Jingjing Rong Junshan Li Zhaofen Zheng Haijun Wang Yanfu Liu Xin Zhong | 2021 | Acta Biochimica et Biophysica Sinica2021，53，4： | 6 |
| 3 | Song Shunxian,Study on Dual-Frequency Planar Monopole Antennas显示文摘 | Zheng Huili Tang Mingxiang | 2005 | IEEE International Symposium on Microwave Antenna Propagation and EMC Technologies for Wireless Communications Proceedings2005，2005，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员